Generate Biomedicines filed for an IPO days after dosing the first patient in Phase III for its lead AI‑designed antibody GB‑0895, targeting thymic stromal lymphopoietin (TSLP) in severe asthma. The SEC filing says proceeds will fund completion of two Phase III trials (SOLAIRIA‑1/2), a Phase Ib COPD study and subsequent development steps. Generate reported sustained biomarker reductions in early trials and projects roughly 1,600 total enrollment across the two Phase III studies. The company has raised $805 million privately and maintains collaborations with Amgen and Novartis, positioning GB‑0895 as a potential long‑acting anti‑TSLP competitor.